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Sempre la pratica deve essere edificata sopra la bona
teorica. [Practice must always be founded on sound
theory.]—Leonardo Da Vinci (1452-1519; provided
the first depiction of a bicuspid aortic valve)
Research on bicuspid aortic valves (BAV) and associated
conditions is increasing exponentially. A major part of the
current knowledge on BAV is derived from investigations
carried out in the clinical setting, especially the surgical
setting, as a consequence of the epidemiologic and surgical
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The Journal of Thoracic and Carexample, most of the stenotic valves explanted at the time
of aortic valve replacement are congenitally malformed.1
However, BAV is most frequently a clinically silent condi-
tion until those complications occur. Thus, although previ-
ous clinical research has contributed to increase the
awareness of the problem, it has been most often limited
by an inherent referral bias related to clinical and surgical
presentation. The current basic knowledge of BAV, particu-
larly its causes, mechanisms, and early interventions, is
probably more limited than generally believed.2,3
Surgical treatment of the most common complications
of congenital BAV is not believed to be a particular chal-
lenge today, at least from a merely technical perspective.
Replacement of the valve and/or the aorta can be per-
formed with very low early mortality and morbidity,
and in the past 20 years, valve repair has become an
additional available option for the regurgitant BAV.4
However, it is now increasingly recognized that the sci-
entific basis for surgical management criteria is still
rudimentary3-6 and persistent gaps in knowledge of the
genetics, pathophysiology, and clinical history of BAV
are responsible for inconsistencies in surgical practice
and lack of a rational and patient-tailored approach.6,7
A recent survey among cardiac surgeons on BAV-
associated aortopathy showed that the timing and tech-
nique of surgical treatment is most often dictated by
surgeon preference or institutional policy rather than
being tailored to the individual patient’s features and
disease characteristics.7 Frequently, the surgeon’s deci-
sion regarding timing of an intervention is even in
disagreement with the current guidelines from profes-
sional societies.4-7
The International Bicuspid Aortic Valve Consortium
(BAVCon) has been created for the purpose of identifying
and addressing current knowledge gaps in BAV, taking
advantage of different sources of data, expertise, multiple
specialties, and available methodologies from different
participating institutions (Appendix E1). The present re-
view focuses on the controversial or unexplored aspects
of BAV that are relevant to the surgical management anddiovascular Surgery c Volume 147, Number 6 1749
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ACC ¼ American College of Cardiology
AVR ¼ aortic valve replacement
BAV ¼ bicuspid aortic valve
BAVCon ¼ International Bicuspid Aortic Valve
Consortium
TAV ¼ tricuspid aortic valve
TAVR ¼ transcatheter aortic valve
replacement750 The Jwill be among the research objectives of the Consortium in
the coming years. Rather than reiterating the state of the art
in surgical management of BAVand its sequelae, this review
highlights the gray zones within current knowledge and the
questions that remain unanswered, and proposes new
research avenues for their resolution.
BICUSPID AORTIC VALVULOPATHY
Two Leaflets Instead of 3: Any Surgical Implications?
In terms of both postoperative in-hospital/30-daymortality
and complications, early outcomes of valve surgery for BAV
do not differ from those for tricuspid aortic valve disease.8,9
Comparing the 2 largest BAV replacement series, it seems
that in-hospital mortality has improved over the decades
from an average 2.8% (1960-1995)10 to 1.5% (1990-
2003).11 Long-term outcomes are satisfactory, in part ex-
plained by the relatively young age of the patients undergoing
surgery for BAV. Reported 15-year survival ranged between
68% and 78% after isolated aortic valve replacement
(AVR),8,12 whereas survival was lower when concomitant
coronary artery bypass surgery was needed10,12: these
figures are not different from those reported for age-
matched patients with a tricuspid aortic valve (TAV).8
Despite such satisfactory surgical outcomes, the scienti-
fic basis on which the current surgical approach to bicuspid
aortic valvulopathy is founded remains defective. Because
recent surgical and clinical research on the topic of BAV
has mostly focused on the associated aortopathy, important
gaps in knowledge remain on the genetic basis, causative
mechanisms, and clinical history of bicuspid valvulopathy.
Although current guidelines for surgical treatment of aortic
valve dysfunction are well supported, they do not distin-
guish between the TAV and BAV,13,14 Yet patients with
BAV disease are generally younger at the time of surgery:
their longer life expectancy compared with patients with
TAV disease implies longer exposure to valve-related com-
plications (eg, structural deterioration of tissue prostheses,
prosthetic endocarditis, and so forth) and greater concerns
about lifestyle (eg, sports, exercise, and so forth), or desire
for pregnancy. The situation is further complicated by
recent studies suggesting that the functional severity of
BAV stenosis, as a consequence of its asymmetric geometry,ournal of Thoracic and Cardiovascular Surcan be greater than assessed by common imaging methods,
and somay be its impact on both ventricular remodeling and
flow alterations in the ascending aorta.15-17 Even the
echocardiographically normally functioning BAV opens
asymmetrically thus causing an abnormal postvalvular
flow pattern and subclinical stenosis.15,18 However, it is
not yet known whether these notions should influence the
timing of surgery. For example, should a mild stenosis be
treated at the time of surgery for ascending dilatation if
the valve is bicuspid? If not replaced, how fast will it
progress to a severe degree or symptomatic stenosis? Can
traditional or newer imaging modalities provide reliable
predictors of valve stenosis progression in the BAV
population? An echocardiography-based valve degenera-
tion score was proposed that proved predictive of aortic
valve surgery in the follow-up19: could computed tomogra-
phybased criteria/indexes, with the inherent better defini-
tion of calcification patterns, add important information to
the current limited capability to predict valvulopathy pro-
gression? Will genetic tests help in this prediction of the
fate of a borderline valve function (Table 1)?Are All BAVs Equal?
A significant source of clinical heterogeneity in BAV dis-
ease lies in the variable morphology of the valve, that is, pat-
terns of congenital cusp fusion (also referred to as
morphotypes).20 Evidence has been presented suggesting
that different genetic substrates could underlie the diverse
morphotypes.21 Arguing against this, however, it has been
recently found that the 2 most frequent morphotypes (fusion
of right-left coronary leaflets and fusion of right noncoro-
nary leaflets) can be interchangeably inherited in familiar
forms of BAV.22 Thus, to compellingly determine the clin-
ical and surgical implications of differences in the valvular
anatomy, future studies will need to include large numbers
of patients for each morphotype. Even within a single mor-
photype, BAVs can be further distinguished for the degree
of leaflet fusion,23 the characteristics of the raphe if present,
and the respective positions of the 2 true commissures.24 All
these features can affect valve biomechanics in terms of
stress and strain,24 that is, stimuli that are known to be
able to promote valve calcification through the pathways
of bone morphogenetic proteins and transforming growth
factor b.25 Thus, a potentially relevant unknown in BAV
surgery is whether gross and subtle anatomic variants
have any prognostic significance and should be therefore
considered in surgical decision making; for example,
whether to spare a normally functioning or mildly dysfunc-
tional BAVat the time of surgery for an aortic aneurysm. To
increase knowledge on these aspects, surgical cohorts
should be specifically stratified according to the valve mor-
photype (Table 1), instead of including all variants under the
same BAV descriptor.gery c June 2014
TABLE 1. Gaps in knowledge and research perspectives in surgery for BAV: key points
Current knowledge Knowledge gaps Proposed strategies to improve knowledge
Bicuspid valvulopathy
Greater flow derangement with BAV stenosis
than with TAV stenosis, for each given
orifice area
Different criteria for indication to AVR according
to valve type (BAV/TAV)?
Comparing the natural history of BAV versus
TAV stenosis. Searching for the predictors of
faster stenosis progression in patients with
BAV
The goal of BAV repair surgery: restoring a
coapting and less stressed valve
Which BAV features affect leaflet stress? Which
technique for annular reduction?
Identifying (bioengineering studies, clinical
series) factors affecting long-term durability of
BAV repair
TAVR in BAV: concerns of noncircular
deployment (risk of perivalvular leak)
Are BAV calcifications always asymmetric and
the orifice always eccentric?
Identifying imaging criteria for definition of a
subset of patients with BAV for whomTAVR is
feasible
Different BAV morphotypes, associated with
unique clinical features and different valve
dysfunction risks
Differential valve surgery approach according to
the morphotype (RL, RN, LN)?
Natural history studies on large populations of
patients with BAV, stratifying according to the
valve morphotype
Bicuspid aortopathy
Diverse BAV morphotypes are associated with
different patterns of aortic dilatation
Different surgical approach to the aorta for
different BAV morphotypes (RL, RN, LN)?
Investigating the correlation between valve type
and aortopathy risk and features
A proportion of patients with BAV experience
acute aortic dissection at small diameters
Any other nondimensional determinant of the
risk of dissection?
Identifying aortic risk markers (other than
diameter): circulating biomarkers, aortic flow
patterns, wall load-bearing properties, genetic
markers, phenotypic markers
Various proposed classification schemes for
the aortic phenotype
Any prognostic significance of the aortic
phenotype; any relevance to surgical timing?
Which classification?
Stratifying longitudinal studies according to the
aortic phenotype. Assessing the prognostic
value of the different classifications in
prospective studies
Different phenotypes of aortic dilatation.
Choice of the procedure often left to the
individual surgeon’s discretion
Surgical technique tailored to the aortic
phenotype?
Exploring the risk/benefit of tailoring the
procedure to the aortic phenotype
BAV, Bicuspid aortic valve; TAV, tricuspid aortic valve; AVR, aortic valve replacement; TAVR, tricuspid aortic valve replacement; RL, right-left coronary leaflet fusion;
RN,right-noncoronary leaflet fusion; LN, left-noncoronary leaflet fusion.
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is advocated also in the setting of transcatheter aortic valve
replacement (TAVR)26: although BAV was initially
excluded from the indications to TAVR in the PARTNER
trial27 because of concerns about the risk of noncircular
deployment of the prosthesis as a result of eccentricity of
the orifice and asymmetry of calcifications, more recent
studies have shown that TAVR can be performed in selected
subsets of patients with BAV at high surgical risk with
similar success as in patients with TAV.26,28 Imaging
methods are available today for detailed morphologic
phenotyping of BAV, and transcatheter prosthesis design
is evolving, therefore the application of TAVR in
inoperable patients with BAV is fertile research ground.
The Purely Regurgitant BAV: Replace or Repair?
Although aortic stenosis in the adult is only treatable by
prosthetic valve replacement, aortic regurgitation can be re-
paired, avoiding anticoagulation-related risks.29 Several
techniques have been proposed, including plication of redun-
dant leaflet tissue, raphe resection and conjoint cusp recon-
struction, pericardial patch augmentation, free-marginThe Journal of Thoracic and Carreinforcement or resuspension, subcommissural stitching,
and suture or ring annuloplasty. Several studies have shown
the feasibility of BAV repair, however midterm durability
has been inconsistent.30,31 It seems logical that the stability
of the repair depends on leaflet tissue quality including the
degree of fibrosis and calcification.29 However, no study
has yet tested the risk/benefit of earlier treatment, aimed at
performing surgery on a better-preserved cusp structure.
Recent evidence indicates that the anatomic features of the
BAV may have a strong prognostic impact on the durability
of repair.32,33 Advancements in our understanding of BAV
geometry and kinematics has led to the notion that late
BAV repair failures might be incited by abnormal leaflet
stresses, inherent to the morphology of the repaired
valve.15,24 In particular, 40% lower rates of 10-year freedom
from valve reoperation have been observed in patients with
an aorto-ventricular junction diameter exceeding 28 to 30
mm compared with patients with a smaller diameter,30,32
leading to the recent development of different strategies for
annular reduction and support.34,35 However, the ideal
correction of annular dilatation still has to be determined
(Table 1).diovascular Surgery c Volume 147, Number 6 1751
FIGURE 1. The research approach to BAVaortopathy: past and future. Up to a few years ago, research on BAVaortopathy interpreted clinical aspects (eg,
rate of progression, relation with severity of valve dysfunction, risk of dissection) with the aim of drawing inferences on the pathogenesis, that is, alterna-
tively supporting the hemodynamic or the genetic theory. Inconclusive results and increasing awareness of the phenotypic heterogeneity have led to an
inversely oriented approach: the contribution of either pathogenetic factor is investigated to identify the respective potential prognostic value in the clinical
setting.6 AVR, Aortic valve replacement; BAV, bicuspid aortic valve.
Expert Review Della Corte et alThe orientation of the 2 true commissures also affects post-
repair outcomes; when the commissures are located 160 to
180 apart, leaflet stresses are lower24 and 10-year freedom
from reoperation rates can be more than 40% higher than in
patients with less than 160 commissural orientation.32,33 It
has been pointed out36 that although repairing a TAV funda-
mentally means restoring normal native anatomy, BAV repair
requires complete rearrangement of valve orifice geometry,
aiming at producing a new,morephysiologicflowarchitecture,
with consequent lower leaflet stresses.15,24 No definitive
evidence has been provided so far in favor or against a
systematic or selective surgical reconfiguration of
commissural orientation. Also the impact of other BAV
morphofunctional details and respective corrective
maneuvers on surgical outcomes (ie, recurrence of
regurgitation) should be the subject of future studies (Table
1). For this purpose, a combination of best-practice imaging
methods andwell-codified surgical approacheswill be critical.BAV-ASSOCIATED AORTOPATHY
From Practice to Pathogenesis or From Pathogenesis
to Practice?
The general research approach to BAVaortopathy has been
inductive in the past, drawing inferences on its pathogenesis
from the observation of clinical presentations and outcomes,
often in the setting of surgical series. However, a tendency to
simplify our view of the problem when translating it into prin-
ciples of clinical practice has caused an exacerbation of the1752 The Journal of Thoracic and Cardiovascular Surdichotomybetweengenetic andhemodynamic theories of aort-
opathy: proponents of the former endorse greater surgical
aggressiveness, those supporting the latter suggest a more con-
servative posture.37,38 This simplistic view has prevented
researchers from focusing on the evidence of phenotypic
heterogeneity of BAV aortic disease. As a result, both
research advances and management innovation have been
hampered. Phenotypic heterogeneity suggests that both
genetic and hemodynamic processes can coexist, each with
variable expression from patient to patient.6 In the light of
this evidence, an inversion of the inductive process is probably
required (Figure 1). Theputativemechanismsof causation, that
is, both genetics and biomechanics, should be thoroughly ad-
dressed with the aim of translating the resulting knowledge
into diagnostic/prognostic tools and criteria. In particular,
new metrics should be developed for the quantification of the
respective contribution of either pathogenetic factor in the indi-
vidual patient or patient subgroup.With this new researchmind
set, and the consequent improved ability to stratify patients
with BAV according to their aortic risk, important surgical
goals may be achieved, including patient-tailored indications
and techniques as well as rationalization of choices.2,6When to Operate on the Aorta: Only a Matter of
Size?
The 2010 American Heart Association (AHA)/American
College of Cardiology (ACC) guidelines for surgical treat-
ment of aortic diseases did not suggest a unique cut-offgery c June 2014
Della Corte et al Expert Reviewdiameter indicating intervention for BAV aortopathy, but
included BAVamong systemic connective tissue abnormal-
ities (Marfan, Elher-Danlos, Loeys-Dietz, and so forth) with
the same recommendations of ‘‘between 40 and 50 mm’’ or
growth rate exceeding 5 mm/y.39 The evidence supporting
those guidelines and the inclusion of BAVamong systemic
syndromes have been the subject of criticism.5,40,41 More
specific criteria were included in the 2012 European
Society of Cardiology/European Association for Cardio-
Thoracic Surgery guidelines for valve diseases, whereby
the cut-off is set at 55 mm, or 50 mm in the case of associ-
ated coarctation, family history of dissection, hypertension
or growth rate greater than 2 mm/y, or 45 mm in the case of
valve surgery.14 However, the level of evidence supporting
current recommendations is still inadequate and guidelines
are mostly derived from expert consensus.6,42
The lack of knowledge and the absence of consistency
between American and European guidelines is echoed by
important divergences in practice. Some investigators11,43
have used a cut-off of 40 to 45 mm for surgical aortic resec-
tion, others a diameter exceeding 40 mm in younger pa-
tients44; others have even reported that in 20% of their
experience, an off-label indication for a diameter of 40
mm or less was used.45 On the other hand, in few European
contemporary series of ascending aorta replacement, a con-
servative criterion of more than 50 mm was followed, even
in the presence of significant valve dysfunction.8,46 Among
100 recently interviewed Canadian cardiac surgeons, only
55% reported replacing the ascending aorta when it
exceeds 50 mm in 50-year-old patients with BAV without
valve dysfunction, whereas 29% were more aggressive
and 16% were more conservative.7
As the anatomic and clinical heterogeneity of BAV dis-
ease is increasingly recognized, it becomes evident that
the debate on surgical indications is a direct consequence
of the lack of data on the prognostic significance of pheno-
typic differences. For example, although right noncoronary
cusp fusion predisposes to earlier development of valve
dysfunction in children, it is still unknown whether the indi-
vidual valvular morphotypes imply a different risk of aortic
events (Table 1). Another source of heterogeneity is the
pattern of aortic dimensions, namely the aortic pheno-
types.47-50 Few and small observational studies have
examined the clinical importance of the distinct BAV
aortic phenotypes. Although the most frequently dilated
segment is the tubular supracoronary tract, predominant
involvement of the aortic root and sinuses has been
associated with faster growth of the aorta and higher rates
of aortic events.51-53 Larger prospective registries could
define whether different dimensional cut-offs for surgery
should be used for the 2 aortic tracts (sinus vs tubular) in
future recommendations (Table 1). In addition, a lack of
uniform methods and definitions of the aortic phenotypes
hinders research efforts; for example, should the definitionThe Journal of Thoracic and Carbe based on the aortic shape (relation between dimensions
at different segments) or should it take the absolute dimen-
sions into account?47-50,54 Moreover, there is no
homogeneity in the methods used for indexing the aortic
dimensions to the patient’s body size. These include the
aortic size index (diameter divided by body surface
area),7,55 the aortic ratio56 (observed diameter divided by
expected diameter, based on the Roman formulas57), and
the cross-sectional area to height ratio.58 The respective
suggested cut-offs for surgical indication36,56,58 may
correspond to different absolute diameters in the same
patient: which index has the best sensitivity and
specificity as a predictor of aortic events? When should
an indexing method be used rather than the absolute
dimension (eg, in patients with low stature, female sex, or
obesity)?
The International Registry of Acute Aortic Dissections,
which included 3% of patients with BAV, demonstrated
that aortic diameter is a poor predictor of acute aortic
dissection, as this dreaded complication occurred at diame-
ters less than 50 mm in about 40% of patients.59 However, a
small study reported only 12% of dissections less than 50
mm in patients with BAV,58 and in a more recent investiga-
tion,60 the mean diameter at dissection in patients with BAV
was 10 mm greater than in patients with TAV. Therefore, the
role of aortic diameter in aortic dissection may be different
for BAV and TAV. Nonetheless, these data were derived
from retrospective analyses58-60 where aortic diameter
was assessed after dissection had already occurred.
Prospective studies will provide important new insights
by determining the rate of aortic dilation and the
predissection diameter; given the relatively low incidence
of dissection in the BAV population,61 a very large study
cohort is needed for this purpose. In addition, other studies
have demonstrated the lack of correlations between aortic
diameter and degree of medial degeneration in the aortic
wall of patients with BAV62 as well as between the degree
of elastic fiber fragmentation and the occurrence of acute
dissection.63 Hence, other important unanswered questions
emerge: does the aortic diameter need to be integrated into a
more complex system of stratification including other risk
markers, so that its relative weight in the decision-making
process can vary case by case according to other prognostic
factors? And what should those other risk markers be
(Table 1)?
The answer may be found by reappraising the pathogen-
esis of aortic dissection as it is currently known. Corner-
stone studies, not stratified for valve type (BAV/TAV),
established that, on average, 6 cm is the critical diameter
at which a steep increase in the risk of rupture or dissection
is observed (of note, no separate analysis was performed for
rupture and dissection).64 This occurs because, in the
average aorta, a 6-cm diameter marks the time point in
the natural history of the aortopathy when tissue remodelingdiovascular Surgery c Volume 147, Number 6 1753
FIGURE 2. Borderline conditions. Intraoperative photographs from a patient with dilated ascending aorta (left: 50 mm at the midascending tract bulging
toward the right and anteriorly, 35 mm at the sinotubular junction, 38 mm at sinuses, and normal distal ascending and arch diameters) and BAV (right: fusion
of the right and left coronary leaflets, partial fibrous noncalcific raphe, a nearly 180 position of the commissures, no stenosis, and trivial regurgitation at
echocardiography). According to published series, different investigators would treat this unique condition by a variety of techniques, including simple
ascending replacement, ascending reduction aortoplasty, ascending and root replacement with valve sparing, Wheat operation, Bentall operation, and so
forth.7
Expert Review Della Corte et alphenomena have presumably altered the mechanical prop-
erties of the wall to the extent that its strength is easily over-
come by wall stress. Ideally, to reach individualization of
surgical indications, in a way to reduce the incidence of
type A dissection as much as possible, we should aim to
measure the key players of the process in a patient-
specific fashion. This might include quantification of wall
remodeling phenomena by assessment of circulating bio-
markers65 or molecular imaging, estimation of wall proper-
ties (thickness, elasticity, stiffness, and distensibility) by
methods of functional imaging,66 measurement or computa-
tion of wall stresses by patient-specific biomechanical sim-
ulations,15,67 and magnetic resonance imaging of flow
patterns.18 When the genetics underlying the risk of dissec-
tion in patients with BAVaortopathy are elucidated, genetic
tests will add dramatically to risk-stratification systems.
This will be one of the main efforts of the BAVCon project.
The Extent of Surgical Aortic Resection
The basic primum non nocere warning for medical prac-
tice is often quoted about surgery for BAV aortopathy:
indeed, an imprudent conservative approach in a patient at
increased risk for dissection but also an excessive extent
of resection in a patient with lower risk can be harmful or
at least unsafe decisions.
Akin to the indications for aortic surgery, the criteria for
the extent of resection are also currently subject to wide var-
iations according to the individual surgeon or center’s pol-
icies7 (Figure 2). In pursuit of a less aggressive approach,
reduction aortoplasty, usually of the midascending aorta,
has been performed by some investigators.68 In selected1754 The Journal of Thoracic and Cardiovascular Surcases, when a shorter operative time is significantly advan-
tageous,4 the success of such an approach may rely on the
localized degeneration of the aortic wall at the greater cur-
vature, which is typically associated with BAV stenosis.69
However, wider application of this procedure, especially
in younger patients with regurgitant BAV, has led to poor
long-term results in terms of dilatation recurrence.48,69
Although guidelines do not endorse proactive resection
of nondilated aortic segments, the general more aggressive
surgical posture toward BAV aortopathy70 has resulted in
more frequent resection of adjacent nondilated segments
in patients with BAV with an isolated aneurysm of the
tubular ascending aorta.44,71 However, both root
replacement and arch procedures add incremental risk to
midascending tract replacement alone, related to coronary
ostia reimplantation and to circulatory arrest,
respectively,5,41 with increased early postoperative
mortality (eg, from 3% to 9% if arch replacement is
added).72
Recent large retrospective studies have demonstrated that
sparing an unaffected root48 or arch73 at the time of
ascending replacement does not expose the patient to a sig-
nificant risk of reoperation in the long term. After resection
of the ascending aorta, the aortic arch in patients with BAV
showed a median growth of 0 mm/y.43 These observations
are consistent with the midascending dilatation being the
most frequently observed phenotype of BAV aortop-
athy.47,52 However, considering the high prevalence of
BAV in the general population (0.5%-2% of all live
births), and the significant proportion of patients with
BAV developing aortic dilatation (30% to>70%),1-4 evengery c June 2014
Della Corte et al Expert Reviewa low percentage of reoperations on the residual aorta
(about 1% in the Mayo series over a median 3-year
follow-up48) may represent a large health care burden. We
advocate that future surgical studies explore the efficacy
of a management strategy based on tailoring the resection
extent to the individual aortic phenotype and consider other
risk-stratifying phenotypic factors as they become avail-
able. This will require comparative studies of the very
long-term follow-up of different subsets of patients with
BAV (Table 1). Besides the different forms of aortic dilata-
tion (ascending phenotype vs root phenotype), other
anatomic, genetic, and biochemical features could prove
of prognostic significance, thus becoming relevant to the
surgical decision. Potential risk-stratifying features may
include effacement of the sinotubular junction,4,48
unicuspid aortic valve,36 associated mitral valve pro-
lapse,51,74 or bovine arch.75CONCLUSIONS
Given its epidemiology and the clinical relevance of
related questions and unknowns, BAV will likely continue
to represent a priority in cardiovascular research. Besides ad-
dressing the strategies and outcomes of surgical treatments
for BAV complications, surgeons will have to collaborate
with imaging experts and basic researchers to elucidate the
mechanisms of development and progression of those com-
plications. BAVCon features a Biobank/Surgery Core whose
memberswill both lead the surgical research onBAVand pro-
vide blood and tissue samples for basic research analyses as
well as clinical data for refined phenotyping.
Future research on BAV will be of multidisciplinary and
translational nature, research objectives will be pursued tak-
ing into adequate consideration the heterogeneity and
complexity of the disease and within a multispecialty,
multicenter registry, so that, ultimately, a clinical approach
to BAV will be based on the concepts of phenotypic and
genotypic stratification and treatment individualization.References
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